Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Change in Account Payables (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Change in Account Payables for 9 consecutive years, with -$1.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Change in Account Payables fell 184.83% to -$1.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.1 million, a 192.96% decrease, with the full-year FY2024 number at -$2.1 million, down 192.96% from a year prior.
  • Change in Account Payables was -$1.1 million for Q4 2024 at SELLAS Life Sciences, up from -$1.8 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.8 million in Q1 2024 to a low of -$1.8 million in Q3 2024.
  • A 5-year average of -$98700.0 and a median of -$228500.0 in 2020 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 1897.22% in 2020, then skyrocketed 735.92% in 2024.
  • SELLAS Life Sciences' Change in Account Payables stood at $1.3 million in 2020, then tumbled by 131.16% to -$401000.0 in 2021, then surged by 406.73% to $1.2 million in 2022, then increased by 7.15% to $1.3 million in 2023, then plummeted by 184.83% to -$1.1 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Change in Account Payables are -$1.1 million (Q4 2024), -$1.8 million (Q3 2024), and -$1.1 million (Q2 2024).